Session: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster II
Hematology Disease Topics & Pathways:
MPN, Chronic Myeloid Malignancies, Diseases, Myeloid Malignancies
Results. A total of 1793 consecutive patients (47% males) was included. The median age at inclusion was 67 yo (IQR 56-75). MPN subtypes were 37% PV, 45% ET and 18% MF. MPN driver mutations were 78% JAK2V617F, 14% CALR and 3% MPL while 5% of the patients had no driver mutation detected. The most frequent MPN treatments were hydroxyurea (HU) or pipobroman (51%), interferon (IFN) (19%), ruxolitinib (12%) and anagrelide (3%) alone or in combination; 15% of the patients did not receive cytoreductive therapy. The majority of patients (80%) received antiplatelet therapy as thrombosis prevention.
A total of 295 episodes of COVID-19 infection were identified in 287 patients, documented in 196 cases by SARS-Cov-2 PCR and/or serology and by clinical history or CT scan for the remaining cases. Seven episodes were asymptomatic, 6 associated with thrombosis (4 pulmonary embolisms, 1 splanchnic, 1 stroke) and 27 with acute respiratory failure. Hospitalization was required for 63 patients (only conventional n= 38, intensive care unit n=25). Cytoreductive treatment was maintained in 88% of the cases, discontinued in 12% and decreased in 1 patient respectively. At last follow-up, 20 patients with COVID-19 had died, as a consequence of the infection for 15 and of MPN (acute transformation) in 3 (2 unknown causes). This yields a global COVID-19 related death rate of 5,2% in these 287 patients. Comparison between the MPN population with and without a COVID infection showed that older age and arterial hypertension were significant risk factors. In contrast, treatment with IFN was associated with less severe forms of COVID-19, the median age of these patients being however younger.
Conclusions. This large observational and prospective cohort of patients with MPN demonstrated a rate of COVID-19 infection of 16%. Among patients with COVID-19, 22% required hospitalization. These rates indicate that the pandemic did not so dramatically affect this specific population of patients, with an overall COVID-related mortality 0.8%. Two hypotheses could be raised for this low rate of infection. One is that MPNs do not constitute an additional risk factor for SARS-CoV-2 infection. On the other hand, patients with MPN may have applied very strictly preventive measures as they were informed of a potentially higher risk in patients with hematological malignancies.
Disclosures: Legros: Novartis: Honoraria; Pfizer: Honoraria, Other: travel accomodation; Incyte: Honoraria; celgene/BMS: Honoraria; Amgen: Honoraria. Boyer perrard: Novartis: Honoraria. Ranta: Janssen: Membership on an entity's Board of Directors or advisory committees. Nicolini: Incyte biosciences: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Novartis Services, Inc.: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Sun Pharma Ltd: Consultancy; KARTOS: Consultancy; Pfizer: Membership on an entity's Board of Directors or advisory committees. Cony-Makhoul: Pfizer, Novartis Pharma, Incyte: Consultancy, Other: Support for travels; Research grants to CH Annecy Genevois for observational and clinical studies, Speakers Bureau. Brignier: OCTAPHARMA: Research Funding; SANOFI,: Research Funding; GILEAD-KITE: Research Funding; AMGEN: Research Funding; THERAKOS: Research Funding; BMS: Honoraria, Membership on an entity's Board of Directors or advisory committees; JANSSEN: Honoraria, Membership on an entity's Board of Directors or advisory committees. James: Novartis: Other: travel accomodation, Research Funding. Kiladjian: BMS: Membership on an entity's Board of Directors or advisory committees; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees; Incyte: Membership on an entity's Board of Directors or advisory committees; AbbVie: Membership on an entity's Board of Directors or advisory committees.
See more of: Oral and Poster Abstracts